At a glance
ClinicalIndex Comparison RecordN/ACompleted· 7,308 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Analysis of Outcomes Among Rheumatoid Arthritis Patients Treated With Xeljanz Versus Biologic DMARDs Using a United States Healthcare Claims Database
In Brief
An observational study for Arthritis, Rheumatoid. Completed, enrolled 7,308 participants across 1 site.
Detailed Summary
To compare rheumatoid arthritis (RA) patient characteristics, adherence, and costs between patients treated with tofacitinib (IR, XR and combined groups) to patients treated with each of the bDMARDs.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
First PostedMay 2019
Primary CompletionApr 2020
TodayJul 2026
First PostedMay 28, 2019
Enrollment StartJan 1, 2019
Primary CompletionApr 6, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.1 years ago